DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1615-1623

  Wallach Dayan, Shulamit Batya ^a,b   Rubinstein, Ariel M ^a   Hand, Carla ^c   Breuer, Raphael ^b,d   Naor, David ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c Kenneth S Warren Institute   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; COMPLEMENTARY DNA; CANCER ANTIBODY; DNA VACCINE; EPITOPE; HERMES ANTIGEN; ISOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DNA IMMUNIZATION; DNA TRANSFECTION; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; ANIMAL; BAGG ALBINO MOUSE; CELL CLONE; CELL CULTURE; CELL PROLIFERATION; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC TRANSFECTION; HUMAN; IMMUNOLOGY; LUNG TUMOR; LYMPH NODE; METASTASIS; PATHOLOGY; PHENOTYPE; VACCINATION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD44; CELL PROLIFERATION; CLONE CELLS; EPITOPES; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PHENOTYPE; PROTEIN ISOFORMS; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINATION; VACCINES, DNA;

EID: 49849096701     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2383     Document Type: Article

References (50)

1. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003;89:1817-21.
2. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine linases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
3. Price LS, Collard JG. Regulation of the cytoskeleton by ρ-family GTPases: implications for tumour cell invasion. Semin Cancer Biol 2001;11:167-73.
4. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001;11:41-7.
5. Feldner JC, Brandt BH. Cancer cell motility - on the road from c-Erbb-2 receptor steered signaling to actin reorganization. Exp Cell Res 2002;272:93-108.
6. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
7. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993;54:271-335.
8. Naor D, Vogt Sionov R, Ish-Shalom D. CD44: structure, function, and association withth e malignant process. Adv Cancer Res 1997;71:241-319.
9. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-79.
10. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 2003;169:1122-33.
11. Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis 2003;20:195-201.
12. Wallach-Dayan SB, Grabovsky V, Moll J, et al. CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. J Cell Sci 2001;114:3463-77.
13. Zahalka MA, Okon E, Gosslar U, Holzmann B, Naor D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol 1995;154:5345-55.
14. Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993;177:443-55.
15. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998;19:89-97.
16. Garin T, Rubinstein A, Grigoriadis N, et al. CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis. J Neurol Sci 2007;258:17-26.
17. Weiss L, Botero-Anug AM, Hand C, Slavin S, Naor D. CD44 gene vaccination ameliorates insulin-dependent diabetes Mellitus (IDDM) in non-obese diabetic (NOD) mice. Isr Med Assoc J 2008;10:20-5.
18. Miyake K, Medina KL, Hayashi S, et al. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med 1990;171:477-88.
19. Weiss JM, Sleeman J, Renkl AC, et al. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J Cell Biol 1997;137:1137-47.
20. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38c13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985;4:191-209.
21. Rochman M, Moll J, Herrlich P, et al. The CD44 receptor of lymphoma cells: structure-function relationships and mechanism of activation. Cell Adhes Commun 2000;7:331-47.
22. Fu YX, Watson G, Jimenez JJ, Wang Y, Lopez DM. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 1990;50:227-34.
23. Medina D, Kittrell FS. Immortalization phenotype dissociated from the preneoplastic phenotype in mouse mammary epithelial outgrowths in vivo. Carcinogenesis 1993;14:25-8.
24. Tolg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993;21:1225-9.
25. Katz BZ, Eshel R, Sagi-Assif O, Witz IP. An association between high Ly-6A/E expression on tumor cells and a highly malignant phenotype. Int J Cancer 1994;59:684-91.
26. Mazzone M, Basilico C, Cavassa S, et al. An uncleavable form of pro-scatter factor suppresses tumor growthand dissemination in mice. J Clin Invest 2004;114:1418-32.
27. Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res 2005;65:2387-96.
28. Pos Z, Safrany G, Muller K, Toth S, Falus A, Hegyesi H. Phenotypic profiling of engineered mouse melanomas withmanipulated histamine production identifies histamine H2 receptor and ρ-C as histamine-regulated melanoma progression markers. Cancer Res 2005;65:4458-66.
29. Nedvetzki S, Golan I, Assayag N, et al. A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor. J Clin Invest 2003;111:1211-20.
30. Bourguignon LYW, Zhu H, Shao L, et al. CD44 interaction with Tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem 2000;275:1829-38.
31. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
32. Rall CJ, Rustgi AK. CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res 1995;55:1831-5.
33. Indinnimeo M, Cicchini C, Giarnieri E, Stazi A, Mingazzini PL, Stipa V. Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncol Rep 2003;10:1875-7.
34. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994;180:53-66.
35. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991;174:859-66.
36. Bartolazzi A, Jackson D, Bennett K, et al. Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J Cell Sci 1995;108:1723-33.
37. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 2006;66:10233-7.
38. Kaufmann M, Heider K-H, Sinn H-P, et al. CD44 variant exon epitopes in primary breast cancer and lengthof survival. Lancet 1995;345:615-9.
39. Bànkfalvi À, Terpe H-J, Breukelmann D, et al. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 1998;33:107-16.
40. Foekens JA, Dall P, Klijn JGM, et al. Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer 1999;84:209-15.
41. Friedrichs K, Franke F, Lisboa B-W, et al. CD44 isoforms correlate withcellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995;55:5424-33.
42. Stauder R, Eisterer W, Thaler J, et al. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995;85:2885-99.
43. Weiss L, Slavin S, Reich S, et al. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 witha specific monoclonal antibody. Proc Natl Acad Sci U S A 2000;97:285-90.
44. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 1995;3:165-9.
45. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996;156:2369-75.
46. + T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J Immunol 1998;160:2425-32.
47. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 1992;89:12160-4.
48. Screaton GR, Bell MV, Bell JI, Jackson DG. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 1993;268:12235-8.
49. Nedvetzki S, Gonen E, Assayag N, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A 2004;101:18081-6.
50. Golan I, Nedvetzki S, Eshkar-Sebban L, et al. Expression of extra trinucleotide in CD44 variant of rheumatoid arthritis patients allows generation of disease-specific monoclonal antibody. J Autoimmun 2007;28:99-113.